Tags Posts tagged with "weed stocks"

weed stocks

0 412

There are so many fronts in the war for marijuana legalization that it’s an arduous task to monitor all of them, yet the job has never been more important. And Last month, the Drug Enforcement Administration stealthy over-stepped its boundaries (again) and advanced its prohibitionist agenda. The mainstream media failed to report this, and it was through Technical 420’s own careful review of recently amended DEA codes that this was uncovered.

In October of 2016, the Cannabis Community was sent in to an uproar when the Department of Justice’s Drug Enforcement Administration tried to make CBD Oil’s illegal by redefining what constituted as marijuana extract under the “Final Rule establishing a new Controlled Substance Code Number (drug code) for marijuana extract”. You can read it here: https://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr1214.htm

The important part of the code can be found under ‘Final Action’ where it states: “Meaning an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant.”

Essentially, last October, the DEA tried to categorize any extract from any part of the marijuana plant as a schedule one substance. This excluded extracts from resin or seeds, however, any other extract was a schedule 1 narcotic regardless of THC content.

Private companies, non-profits, and advocacy groups struck back with lawsuits claiming the law was over-reaching. And it seemed that the DEA backed off, and the cannabis community sighed a breath of relief.

However, sometime last month, the DEA quietly and unannounced posted an amendment to the code. The mainstream media, and even most CBD manufacturers, failed to pick it up this new posturing from the DEA. You can read it in full here:


Under the “Clarification of the New Drug Code (7350) for Marijuana Extract” the definition of marijuana extract changes. While they do make changes to better structure their own legal grounds on the definition of what is marijuana extract, the important part of this updated code is that now anything extracted from marijuana is also included as a schedule one substance.

Just to highlight how absurd this is, consider that you can extract pure omega fatty acids from cannabis resin. No cannabinoids, no THC, just Omega (like 3, 6, & 9) Fatty Acids. The DEA literally just claimed that Omega Fatty Acids are a schedule 1 controlled substance when extracted from cannabis. Enough said.

To be as clear as their new rule is: Anybody selling CBD oil is now undoubtedly and unequivocally selling a schedule 1 substance. Seeds, while still not included in the code, are the only part of the cannabis plant that cannot produce quality CBD oils, just hemp oil.

It now is clear that their goal is to strengthen their positioning in their upcoming court battles over CBD’s scheduling classification. The updated code attempts to redefine CBD to include extracts and attempts to skirt around most of the legal claims of law suits already in the courts dockets. It’s an incredibly unethical and corrupt move.

Not to mention, these codes do not come from elected officials, but rather from bureaucratic actions that do not represent the American people. We will, of course, be keeping an eye on this latest development very closely.

Authored By: Jason Spatafora

0 202

Up until its legalization, marijuana has been a black-market business relying solely on cash. As the business moves out of the shadows and gets it rightful government oversight, new regulators have been hired to make sure laws are being followed. All of these regulators have no experience given the nature of the industry being brand new.

The result of this can sometimes be a perfect mixture for government corruption.

Many recent cases noted in Colorado and Washington have dealt with the issue of current or former marijuana regulators and their accusal of improper dealings within the industry of legal cannabis. This is shocking given that the two recreational marijuana states have the oldest recreational programs in the country, having weed legalized in defiance of federal law since 2012.

A few cases several years into marijuana’s legalization may not seem like a big deal to many, but all it takes is a few to make a large dent in the confidence behind a medical marijuana industry. This can also bring back the feeling that the industry is criminal and fuel many fears behind its illegitimacy.

One of the cases states that former Colorado marijuana enforcement officer Renee Rayton, is accused of helping pot growers grow plants for use in out-of-state sales.

After being accused, state investigators say that the former inspector quit her job and immediately went to work for the illegal pot ring, yielding an eight thousand dollar per month job.

In Washington, the state agency behind regulating marijuana recently fired an employee who controlled the leasing of land to a prospective pot grower.

The man behind the accusal is named Grant Bulski. Bulski was charged with leasing twenty-five acres of land to a marijuana entrepreneur for close to three-thousand dollars per month. The law forbidding this states that pot regulators cannot have a financial state in the businesses, however Bulski was not charged with any crime.

These may be just a few cases concerning the affects of the recreational marijuana, but all it takes is a few to take the public into believing the market is illegitimate. However, do some research and quickly find that the market has a history of legitimacy and medicinal benefit to all who use.

0 303

Canabo Opens Second Nova Scotia Clinic and Announces Appointment of Garry Stewart as Chief Financial Officer

As previously discussed on June 5 in the Company’s Corporate Update, the clinic reports new patient volumes continue at record levels.

Dr. Neil Smith, Executive Chairman of Canabo Medical Inc. stated, “As explained in our June 5th Corporate Update we reiterate, there was no fundamental reason for the sharp decline in our share price during May. The Company’s operating fundamentals and growth trajectory remain strong.”

Canabo also announces today the appointment of Mr. Garry Stewart as Chief Financial Officer.

Mr. Stewart is a Chartered Professional Accountant who brings over 25 years of professional experience to the role. Prior to joining Canabo, Mr. Stewart served as CFO, Vice President Finance at TAR Investments Ltd., including Datarite Ltd. and Atlantic Business Interiors Ltd.

Mr. Stewart replaces Mr. Rob Randall as Chief Financial Officer. Mr. Randall is leaving Canabo to focus on his other CFO roles but will continue to support and assist Mr. Stewart during the transition. John Philpott, President & CEO of Canabo, commented, “I would like to thank Rob for his service to Canabo. He played a key role in the RTO transaction as well as the growth of the business. We wish him well in his future endeavours.”

About the Company

Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo now has 22 clinics across Canada, with additional locations planned to open in 2017. Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.

Forward-Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, the Company’s ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

0 326

Although many people associate the legal cannabis industry with the growing and selling of marijuana, the industry has evolved into much more than that.

Canada has proven itself to be a profitable new frontier for cannabis investors and we think this is just the first inning of a multi-decade growth cycle. While licensed producers have been at the forefront of this movements, new opportunities have emerged within the Canadian cannabis market and we want to highlight two undervalued opportunities

Reliq Management Converts Debenture at a Premium

One of the most important metrics to look at when it comes to cannabis stocks is insider activity. When insiders are buying stock in their own company, it is a positive and helps reaffirm the long-term value proposition of the company. When insiders are selling, it is typically not a good sign.

Reliq Health Technologies (RHT.V) (RQHTF) is a stock we have been favorable on as the company continues to execute on its previously announced initiatives and work towards creating value for its shareholders.

Earlier this week, Reliq CFO Amandeep Thindal converted his $100,000 debenture into equity at $0.13 cents, a premium to yesterday’s closing price. This is a bullish sign for Reliq and we see value in the shares at current levels. The company significantly strengthened its balance sheet and closed an oversubscribed financing round. The company raise $763,000 after initially planning to raise only $500,000.

Over the last quarter, Reliq has significantly advanced and improved its fundamental story as it created new strategic partnerships, commenced new pilot programs, and started to generate recurring revenue.

Reliq is focused on securing new contracts with home care agencies, assisted living facilities and hospitals in North America. The company expects to achieve profitability by the end of 2017. We are favorable on Reliq due to its ability to disrupt a multi-billion-dollar market, its management team, its pilot programs, and its valuation.

Lexaria Strengthens its Patent Portfolio

Today, Lexaria Bioscience Corp. (LXRP) (LXX.CN) filed a new provisional patent application with the US Patent and Trademark Office. The new patent application expands Lexaria’s lipophilic food and beverage composition claims to include microwave (dielectric energy) processing as well as heating/dehydration in a vacuum environment.

The patent application covers processing of cannabinoids, vitamins, NSAIDs and nicotine. Lexaria believes that its patent portfolio is the broadest of any comparable company in North America. Lexaria has 19 patent applications filed and pending in more than 40 countries worldwide.

This development is significant and follows the company’s successful application in October 2016 when Lexaria was issued United States Patent pertaining to its method of improving bioavailability and taste of certain cannabinoid lipophilic active agents in food products.

Lexaria’s technology makes cannabis edibles taste better and makes the active ingredients enter the bloodstream more quickly and much more effectively. The patent protects Lexaria’s intellectual property related to the primary focus of its business, the infusion of cannabinoid compounds in edible products.

Authored By: Jason Spatafora

0 386

Canopy Growth (WEED.TO) (TWMJF) has rallied 25% off its June lows and the shares have been trending higher ahead of the company’s fourth quarter and full-year earnings report.

Before the market opens on June 27th, Canopy will release its fourth quarter financial and operating results and we expect to see the company report strong numbers for the period.

Last week, Canopy Growth provided shareholders with a corporate update and the market responded very favorably to this update.

A Global Expansion Story

From Germany to Australia, this Canadian licensed medical marijuana producer continues to increase market share across the globe and we expect this to trend continue as management continues to execute.

Canopy announced that it is renaming its German subsidiary to Spektrum Cannabis Germany GmbH and confirmed ongoing sales of Tweed-branded products in Germany with sales growth accelerating rapidly on a month-over-month basis. Spektrum Cannabis Germany GmbH has now distributed cannabis products to over 480 pharmacies across Germany, up from 200 pharmacies in April 2017.

The company also established a new subsidiary for its entrance into Chile’s market, Spectrum Chile SpA. Canopy will enter this market with the creation of a new product, Spectrum Chile. This product will complement Canopy’s expansion into South America and Canopy Growth plans to position itself as a leader in the Chilean market.

Through a strategic partnership with a domestic Chilean medical cannabis company, Spectrum Chile will work to ensure Chilean patients have access to high-quality cannabis products.

A Company of Firsts

Canopy Growth has been a leader in the global cannabis market and the company has benefited from having a first mover advantage.

In April 2014, Canopy Growth became the first cannabis company in North America to be publicly traded. The company followed was also the first to diversify its platform to include both greenhouse and indoor growing, to acquire a major competitor and to be listed on the Toronto Stock Exchange, and the only cannabis company to be a member of a major global stock market index (S&P/TSX Composite index).

Canopy was the first Canadian producer to be approved to export dried cannabis to Germany through its Tweed subsidiary, and its wholly-owned German subsidiary continues to offer several varieties for sale through German pharmacies.

Canopy recorded another milestone this month by becoming the first company to start selling softgel capsules in Canada. This product offers consumers a new way to consume cannabis and they are being produced at Canopy’s Smiths Falls campus. Canopy will offer this product through the Tweed Main Street store, which serves over 58,000 customers.

A Favorable Outlook

We are favorable on Canopy Growth Corp due to the following reasons: 1) It is the largest and best capitalized medical cannabis producer, 2) The company continues to execute on its initiatives and work toward creating value for its shareholders, 3) Management has a proven track record of success, 4) The company continues to report earnings that show improving fundamentals, and 5) Its balance sheet is flush with cash and leaves the company flexible and able to expand through both organic and inorganic growth initiatives.


Authored By: Jason Spatafora

0 324
Marijuana Stocks Cannabis Stocks

A legal cannabis movement is sweeping the United States and currently, 29 states and the District of Columbia have legalized medical marijuana and eight states have legalized recreational marijuana.

Although recent studies have shown that cannabis has medical benefits, the DEA and FDA still have it classified as a Schedule I substance. The Schedule I category is reserved for substances that have the highest potential for abuse, that have no accepted medical use and even under medical supervision cannot be used safely.

Although researchers are beginning to learn about the medical benefits associated with cannabis, they have not even scratched the surface. The cannabis industry is the fastest growing industry in the world. After spending several years researching cannabis and developing products, companies are just beginning to realize the fruits of their efforts.

Biotech Beneficiaries

The biotech sector will be one of the greatest beneficiaries of the legal cannabis movement and we expect this market to see incremental growth over the next decade.

Cannabis continues to improve daily life for millions of people all over the globe and this multi-billion-dollar opportunity is still in its infancy. The biotech sector of the cannabis industry is comprised of some of the best capitalized and most mature public companies and we have identified five companies for investors to monitor.

IGC: A Stock to Watch After Coming Off its Highs

India Globalization Capital (IGC) is one of the few cannabis-focused companies that trade on the New York Stock Exchange (NYSE) and earlier this month, the company entered a definitive license agreement with the University of South Florida (USF). Under the agreement, IGC is the exclusive licensee of the U.S. patent filing entitled, THC as a Potential Therapeutic Agent for Alzheimer’s Disease.

This is an important development and milestone for the company as it works toward the development of a potential cannabis-based blockbuster treatment for America’s most expensive disease, Alzheimer’s disease.

IGC received a muted reaction from the market and we see upside to current levels after this milestone. We are favorable on IGC’s recent updates as it has pivoted fully into the biotech cannabis sector and continue to monitor developments around the company’s cannabinoid-based therapies.

Insys Receives a Positive Response to Management Additions

Insys Therapeutics (INSY) continues to trade higher after the company announced the addition of four pharmaceutical industry veterans to its management team. These additions help remove some of the market’s concerns pertaining to the strength of its management team and we see further upside from current levels.

we view Insys as an acquisition candidate and expect to see the company acquired this year. In July 2016, INSY announced that the FDA approved Syndros, an orally administered liquid formulation of the pharmaceutical cannabinoid Dronabinol, a pharmaceutical version of THC. At the time of this announcement, INSY said that Syndros is awaiting scheduling by the DEA.

GW Pharma: An Industry Leader

GW Pharmaceuticals (GWPH) has come off its recent lows and the shares are trading near $105 after falling below $93 earlier this month. GW is an industry leader and the company has several catalysts occurring in the second half of this year.

GW is changing the landscape of the biotech industry and the company already sells a cannabis-derived treatment for multiple sclerosis is 27 countries. GW is a company that investors need to watch as it continues to execute on its pipeline and create value for shareholders.

Nemus Advances its THC Pro-Drug

Today, Nemus Bioscience (NMUS) announced that tetrahydrocannabinol (THC) derived from NB1111, a proprietary pro-drug of THC, achieved significant tissue concentrations in multiple compartments of the eye that are correlated with the lowering of IOP in a normotensive ocular animal model.

The abstract, Intraocular pressure lowering efficacy of NB1111 in a normotensive rabbit model expands on previously reported data by showing that the product safely penetrated multiple ocular chambers and concentrated in key tissues that help regulate intraocular pressure.

Nemus and the University of Mississippi have also collaborated on developing an analogue of CBD into an eye drop formulation called NB2222. The company plans to submit an abstract to an upcoming scientific meeting to present data on the NB2222 program.

We are favorable on this development and view Nemus’ relationship with the University of Mississippi to be a unique and differentiating factor. The shares are trading at $0.28 and this is a company investors should watch.

Cara Surges 10% on Positive Data

Cara Therapeutics (CARA) rallied more than 10% yesterday after the company announced the completion of a pre-specified interim conditional power analysis of its adaptive Phase 3 trial of I.V. CR845. The trial will continue to test two doses of CR845 against a placebo in up to 450 patients undergoing abdominal surgery. The Independent Data Monitoring Committee (IDMC) reviewed available safety information and confirmed that both doses of CR845 were well tolerated with no significant changes in the monitored safety parameters.

The primary efficacy measure is the Change in Pain Intensity over the 24-hour postoperative period using the patient-reported Numeric Rating Scale score collected at pre-specified time points through 24 hours. Postoperative nausea and vomiting will be evaluated as a secondary efficacy measure.

Although CARA has not advanced any of its cannabis initiatives, we continue to monitor the shares closely. Although we do not consider CARA to be a cannabis biotech stock, we continue to monitor the shares due to the potential it has to enter the sector.

Authored By: Jason Spatafora

0 437

In February, the cannabis industry recorded a major milestone when Australia became the first continent to legalize medical marijuana.

The legislation amended the Narcotic Drugs Act and allows for the cultivation of marijuana for medical and scientific purposes. Following the passing of this legislation, Australian Health Minister Sussan Ley made the following statement:

“This is an historic day for Australia and the many advocates who have fought long and hard to challenge the stigma around medicinal cannabis products so genuine patients are no longer treated as criminals. This is the missing piece in a patient’s treatment journey and will now see seamless access to locally-produced medicinal cannabis products from farm to pharmacy.”

iCAN Australia is Born

Australia represents a new opportunity for cannabis companies and yesterday, iCAN: Israel-Cannabis entered the market by forming a joint venture with LeafCann Research and Advisory. The partnership, iCAN: Australia will collaborate on a range of initiatives including medical cannabis research, innovation, acceleration, and education.

iCAN: Israel-Cannabis CEO Saul Kaye stated, “We are thrilled to partner with LeafCann to form iCAN: Australia. Our collaboration will bring world-class cannabis products to the Australian market as well as accelerate our collaborative research and development of new products for a range of indications.”

LeafCann’s practitioner education program will be incorporated into iCAN’s product offerings and distributed by iCAN. iCAN: Australia will take a significant interest in CannaTech Australia, a medical cannabis summit modeled after CannaTech’s events in Israel.

Canadian Titans Have the Early Mover Advantage

Although iCAN is not the first company to target the Australian cannabis market, it has taken a different approach when compared to the other companies that have entered the market.

Earlier this year, Cann Group announced that Aurora Cannabis (ACB.V) (ACBFF), a licensed medical cannabis producer in Canada, acquired 19.9% of the company ahead of its initial public offering.

Canopy Growth (WEED.TO) (TWMJF), the largest licensed medical cannabis producer in the world also entered the Australian medical cannabis industry through a partnership with AussCann (ACNNF). Canopy Growth will help AussCann increase market share and capitalize on the Australian cannabis market.

Global Expansion Continues

Marijuana legalization may not be a top priority for the United States right now, but change is occurring all over the world. The global marijuana industry has gathered support from many high-ranking officials over the last two years which has increased overall support for the reform of restrictive laws.

Progress toward this goal is hampered by political realities, such that cannabis is still classified as a Schedule I substance. It is time for change and for the authorities to recognize its medical benefits and to remove some of the restrictions that are not supported by scientific research.

Not only is this a medical necessity, but it just makes good business sense.

Authored By: Jason Spatafora

0 229

Cannabis Science Releases the Chronic Pain CBIS Transdermal Patches to Meet the Overwhelming Demand from Self-Medicating Patients Worldwide as it Continues to Expands its California Dispensary Network

“The CBIS medicated adhesive transdermal patch is placed on the skin to deliver a specific dose of cannabinoid medications into the bloodstream. Self-medicating patients have been reporting promoted healing effects to specific injured areas of the body experiencing chronic pain. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch can provide a controlled release of the medication into the patient, usually through a porous membrane covering a reservoir of medication or body heat that melts thin layers of high potency cannabinoid formulations embedded in the adhesive; the medication slowly enters the bloodstream at the chronic pain spot and then penetrates the central nervous system delivering the pain relief reported by self-medicating patients,” said Dr. Allen Herman, Chief Medical Officer of Cannabis Science.

As well, CBIS continues to grow its distribution network in Los Angeles, California by adding Kush Factory as CBIS’ newest Spotlight Dispensary for the month of July 2017.

Kush Factory is the latest dispensary to join the Cannabis Science new product distribution network and has received most of the recently released CBIS products, including the previously sold-out CBIS Metered Dose Inhalers (MDI) and the existing line of extracted tinctures, pills, sprays, balms, suppositories, and creams along with the upcoming release of more targeted controlled delivery modules.

As Spotlight Dispensary of the Month of July 2017, Kush Factory will be the first dispensary to carry the highly anticipated Chronic Pain CBIS Transdermal Patches.

The Kush Factory
612 N Vermont,
Los Angeles, California 90004

Please contact Kush Factory directly for ordering all CBIS products and delivery schedules.

The CBIS MDI’s continue to be highly sought after and the company is working to increase production to meet strong demand from patients. The CBIS Unisex Suppository Regimen Package consists of rectal suppositories, and is the first of three regimen packages including a separate female and male package for self-medicating patients who prefer alternate delivery methods that will be released by CBIS.

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statement

 This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.

0 229

Reliq Health Announces Closing of Oversubscribed Non-Brokered Private Placement with Gravitas Securities as Exclusive Financial Advisors

Each Unit each consists of one (1) common share (the “Common Share“) and one half (1/2) transferrable share purchase warrant (the “Warrant“). Each of the 3,468,600warrants entitles the holder thereof to purchase one (1) additional Common Share on or before June 21, 2019 at a price of CDN$0.165 per Common Share.

“We’re very pleased to complete a successful oversubscribed offering,” said Dr. Lisa Crossley, CEO of Reliq. “Gravitas played an instrumental role in the success of the private placement as exclusive advisor.”

In accordance with the policies of the TSX Venture Exchange, the Company paid Finders’ Fees of an aggregate of $61,047.36 in cash and an aggregate of 554,976 finder warrants (the “Finder Warrant“). Each Finder Warrant will entitle the holder thereof to purchase one (1) additional Common Share on or before June 21, 2019 at a price of CDN$0.165per Common Share.

The securities issued are subject to a 4 month hold period that expires on October 22, 2017.

About Gravitas Securities Inc.

Gravitas is known for sophisticated sector expertise, tactical individuals with a commitment to excellence, global integration and innovation, and as a leading independent wealth management and capital markets firm. Gravitas provides a wide range of investment mandates and services for retail and corporate clients globally from offices in Toronto, Vancouver, and Calgary, and is represented in the United States through its FINRA representative, Gravitas Capital International, in New York and San Francisco.


Dr. Lisa Crossley, CEO and Director

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the “Company“) does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

0 229

Lexaria Files New Patent Application

Lexaria has successfully filed a new provisional patent application with the US Patent and Trademark Office (“USPTO”), No. 62/519,511, with a filing date of June 14, 2017. The new patent application expands Lexaria’s lipophilic food and beverage composition claims to now include microwave (dielectric energy) processing as well as heating/dehydration in a vacuum environment.

The patent application covers processing of cannabinoids, vitamins, NSAIDs and nicotine. The acceptance by the USPTO of this new application is another step in Lexaria’s process of continually strengthening its intellectual property portfolio utilizing all of the most commonly used food processing techniques available. Lexaria believes its current cannabinoid-related patent portfolio to be the broadest of any comparable company in North America.

Separately, Lexaria has engaged a new Manager of Corporate Communications who is being awarded 200,000 stock warrants priced at US$0.295 which expire on June 21, 2019. The Manager of Corporate Communications is also receiving 300,000 stock options priced at US$0.295 that expire on June 21, 2022, and which vest as to 100,000 on each of June 22, 2018; June 22, 2019; and June 21, 2020.

Lexaria is awarding 50,000 stock options to each of two long-standing consultants that vest immediately and expire on June 21, 2022. The options are priced at US$0.295.

Lexaria is awarding 210,000 restricted common shares to each of two officers who have met intellectual property performance thresholds within their existing consulting contracts with the Company.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Lexaria has 19 patent applications filed and pending in more than 40 countries worldwide.

About Lexaria

Lexaria Bioscience Corp. is a biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been proven to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.



This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria Energy Foods, Amarii, and ViPova™ products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements